Treatment of genital warts in males by pulsed dye laser

Badawi, Ashraf; Shokeir, Hisham; Salem, A.M.; Soliman, Mona; Fawzy, Sahar; Samy, Nevine; Salah, Manal

doi:10.1080/14764170600617490

Cited by 16 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Badawi et al (19) used 585 nm PDL in the form of three to four overlapping pulses with higher fluencies (9 to 10 J/cm²) to treat 174 male patients with anogenital warts, and they reported a 96% complete clearance rate. This was achieved after one to three sessions with 2-week intervals between.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pulsed-dye laser versus intralesional Candida albicans

Elmaadawy¹,

Shams²,

Hegab³

et al. 2019

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

Introduction: Genital warts are a troublesome therapeutic issue. Pulsed-dye laser (PDL) is a non-ablative therapeutic tool for viral warts. Intralesional Candida albicans (C. albicans) immunotherapy has yielded promising results in treatment of various types of warts. We aimed to evaluate the effectiveness of PDL versus C. albicans immunotherapy for treatment of genital warts. Methods: Forty adult patients with genital warts were divided into two equal groups; the first was treated using PDL and the second using intralesional C. albicans antigen injection. Treatments were performed at 3-week intervals until complete lesion resolution or for a maximum of three sessions. Results: PDL yielded higher complete clearance rates (95%) than C. albicans antigen (50%; p = 0.001), which in turn had the advantage of treating distant and internal genital warts. Apart from pain during the session in PDL, both modalities were well tolerated with no recurrence in cured patients during the 16-week follow-up period. Conclusions: PDL and C. albicans antigen injection are safe and effective treatment alternatives for genital warts. PDL yielded better frequencies of clearance, but C. albicans antigen has additional advantages, including a single injection site and treating distant and internal mucosal uninjected warts, which are usually difficult to treat.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, the results of Komericki et al (18) showed no recurrence in the treatment areas, but 22% of their patients developed new genital warts in other locations than those treated after PDL treatment. Badawi et al (19) reported a recurrence rate of 5% in genital warts after one to three sessions of PDL treatment.…”

Section: Discussionmentioning

confidence: 99%

Pulsed-dye laser versus intralesional Candida albicans

Elmaadawy¹,

Shams²,

Hegab³

et al. 2019

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

show abstract

“…A total of 174 adult male patients with 550 uncomplicated anogenital warts received treatment with PDL. Complete resolution was achieved in 96% of lesions with a recurrence rate of 5% with minimal adverse events 19 …”

Section: Genital Human Papilloma Virusmentioning

confidence: 94%

“…Complete resolution was achieved in 96% of lesions with a recurrence rate of 5% with minimal adverse events. 19…”

Section: Lasersmentioning

confidence: 99%

Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

et al. 2010

View full text Add to dashboard Cite

Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence-based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.

show abstract

“…As pointed out by Tsao et al, 2 there are three types of scars: (1) atrophic scars (most commonly seen in acne and As has been widely reported, FPDL may also be used on nonvascular lesions, including viral infections such as molluscum contagiosum, or hyperplastic lesions such as xanthelasma palpebrarum. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]…”

Section: Introductionmentioning

confidence: 99%